Boardroom Alpha
Start trial
8-K primary document
CDT · Current Report (Form 8-K) · Filed February 24, 2026

Cdt Equity Inc — 8-K exhibit

ex10-3.htm
Cdt Equity Inc on Boardroom Alpha

 

Exhibit 10.3 

 

ADDENDUM #1

TO CONSULTING AGREEMENT

 

This Addendum #1 (the “Addendum”) is entered into as of February 24, 2026 (the “Addendum Effective Date”), by and between CDT Equity Inc., a Delaware corporation (the “Company”), and Thesprogen, PC, (the “Consultant”).

 

This Addendum amends that certain Consulting Agreement entered into by the Parties effective as of December 28, 2025 (the “Agreement”). Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Agreement.

 

1. Extension of Term

 

Pursuant to Section 12 of the Agreement and the final paragraph of Appendix A, the Parties hereby agree to extend the Term of the Agreement for an additional twelve (12) months following the expiration of the initial six (6) month term.

 

Accordingly, the Agreement shall remain in full force and effect through June 28, 2027, unless earlier terminated in accordance with the Agreement.

 

2. Additional Compensation

 

In consideration for the continued provision of the Services during the extended Term, the Company agrees to pay the Consultant an additional fixed retainer of $245,000 (Two Hundred and Forty-Five Thousand Dollars) (the “Extension Retainer”).

 

The Extension Retainer shall be earned upon execution of this Addendum and shall be payable within ten (10) business days of the Addendum Effective Date.

 

The Extension Retainer shall be satisfied in shares of the Company’s common stock. The number of shares to be issued shall be determined by dividing (i) $245,000 by (ii) the closing per-share price of the Company’s common stock as listed on The Nasdaq Stock Market on the last trading day immediately preceding the Addendum Effective Date (the “Reference Price”), with any fractional shares rounded up to the nearest whole share. Such shares shall be fully vested and fully paid and nonassessable upon issuance.

 

3. No Other Amendments

 

Except as expressly amended hereby, all terms and conditions of the Agreement shall remain unchanged and in full force and effect. In the event of any conflict between this Addendum and the Agreement, this Addendum shall control.

 

4. Counterparts

 

This Addendum may be executed in counterparts and in PDF form or by other electronically transmitted signatures, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[Signature Page Follows]

 

 

 

 

IN WITNESS WHEREOF, each Party has caused the Agreement to be executed effective as of the date set forth above.

 

AGREED TO:  
CDT Equity Inc. (Company)  
     
   
Name: James Bligh  
Title: Chief Financial Officer  
     
AGREED TO:  
Thesprogen, PC (Consultant)  
     
   
Name:  
Title:  

 

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer